What Is Happening With Pulse Biosciences Stock Today?

Pulse Biosciences Inc (NASDAQ: PLSE) shares are tumbling after announcing an update to its recent FDA 510(k) submission to add sebaceous hyperplasia to expand the CellFX System's current labeling.

• The Company received an Additional Information (AI) letter, stating that the Company did not provide sufficient clinical evidence for the expanded use of the system.

• The letter also notes that the Company had not met the primary endpoints of the sebaceous hyperplasia FDA-approved IDE study.

• The Company anticipates meeting with the FDA to discuss the contents of the AI letter and potential next steps, which may require additional clinical data and potentially a new 510(k) submission.

• Based on FDA guidance, the Company believes its meeting with the FDA will be in Q1 2022.

• In Europe, the CellFX System is approved for sebaceous hyperplasia, seborrheic keratosis, and non-genital warts.

• In the U.S., the CellFX System is cleared for dermatologic procedures requiring ablation and resurfacing of the skin and treating benign lesions.

• Price Action: PLSE shares are down 33.3% at $7.24 during the market session on the last check Tuesday.

See more from Benzinga

• Johnson & Johnson Halts Production Of Its COVID-19 Vaccine: NYT

• Karyopharm Shares Fall After Selinexor Data In Endometrial Cancer Patients

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.